ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

House: NCI Should Coordinate National Cancer Program

August 4, 1995

In Brief: Changes In Key Subcommittee chairmanships, Brooke’s Defeat Leave Direction In Doubt

November 17, 1978

FDA News: Rep. Barton Expresses “Concern” About Plan To Merge Offices

May 22, 1998

TTF Increased Survival Compared To Chemotherapy

December 31, 2010

Firm Begins Phase II Trial Of LDP-341 For Myeloma.

March 30, 2001

Sustained-Release Leuprolide Under Study In Phase III Trial.

June 30, 2000